Dr. Vered Stearns, MD

Dr. Stearns practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Stearns' NPI, 1861420945, was assigned on June 29, 2006. Dr. Stearns graduated from Rutgers Robert Wood Johnson Medical School in 1992. Dr. Stearns holds New York license 326987.

Dr. Stearns' primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Stearns' primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. Dr. Stearns is also affiliated with Hospital for Special Surgery. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Stearns to 1 more hospital, 2 clinical labs and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stearns practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Stearns' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Stearns' licenses on file in 3 states: New York, District of Columbia and Maryland.

Dmand AI lists breast cancer among the conditions Dr. Stearns treats.

CMS data shows 176 Medicare services from Dr. Stearns across 3 procedure codes in 2024, all of them office visits, for 53 Medicare patients. Medicare paid $22,685 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 53 Medicare patients who saw Dr. Stearns in 2024. The largest group is 75 to 84, with 24 patients. 75% of them have cancer, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Stearns' median patient age at 67, with 96% women.

In 2024, Dr. Stearns wrote 49 Medicare Part D claims for 18 patients. 92% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $457 in total drug cost. In 2023, CMS named 39 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Stearns for performance year 2024, reported through an alternative payment model (APM). Dr. Stearns accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Stearns as offering telehealth.

Dmand AI links 146 papers to Dr. Stearns, published from 2007 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Breast Neoplasms, Chemotherapy, Adjuvant and Aromatase Inhibitors. Dr. Stearns has published most often in Breast Cancer Res Treat. Dr. Stearns' most frequent co-authors are Antonio Carlos Wolff, MD, Roisin M. Connolly, MB and John H. Fetting, MD.

CMS Open Payments shows 32 general payments to Dr. Stearns from 5 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $48,893. It also lists 3 research payments totaling $8,439 from 2021 to 2024.

Dmand AI lists 1 award for Dr. Stearns, most recently CMS Stage 1 EHR in 2014.

Dr. Stearns graduated from Rutgers Robert Wood Johnson Medical School in 1992.

Dr. Stearns is in network with 15 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.